Aura Biosciences, Inc.
AURA
$5.36
-$0.04-0.74%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.46% | 10.83% | 6.68% | 7.65% | 9.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.09% | 19.62% | 23.11% | 31.28% | 40.96% |
| Operating Income | -13.09% | -19.62% | -23.11% | -31.28% | -40.96% |
| Income Before Tax | -13.81% | -17.16% | -18.00% | -23.77% | -29.79% |
| Income Tax Expenses | -17.52% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.76% | -17.48% | -18.26% | -24.06% | -30.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.76% | -17.48% | -18.26% | -24.06% | -30.03% |
| EBIT | -13.09% | -19.62% | -23.11% | -31.28% | -40.96% |
| EBITDA | -13.38% | -20.00% | -23.46% | -31.83% | -41.57% |
| EPS Basic | 9.15% | 11.27% | 10.81% | 6.10% | 1.74% |
| Normalized Basic EPS | 9.34% | 10.82% | 10.32% | 5.59% | 1.16% |
| EPS Diluted | 9.15% | 11.27% | 10.81% | 6.10% | 1.74% |
| Normalized Diluted EPS | 9.34% | 10.82% | 10.32% | 5.59% | 1.16% |
| Average Basic Shares Outstanding | 25.32% | 32.56% | 32.80% | 32.59% | 32.34% |
| Average Diluted Shares Outstanding | 25.32% | 32.56% | 32.80% | 32.59% | 32.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |